CTA
TGTX icon

Carillon Tower Advisers’s TG Therapeutics TGTX Stock Holding History

Carillon Tower Advisers’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$51.6M Sell
992,041
-49,302
-5% -$1.67M 0.31% 106
2020
Q3 		$27.9M Buy
1,041,343
+49,302
+5% +$1.13M 0.37% 85
2020
Q2 		$19.3M Buy
+992,041
New +$16M 0.15% 203

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Carillon Tower Advisers's TGTX Position: Q4 2020 in Review

Carillon Tower Advisers reduced its TG Therapeutics (TGTX) stake by 4.7% in Q4 2020, selling an estimated $1.67M and leaving 992,041 shares worth $51.6M. The position accounts for 0.31% of the portfolio, ranked #106.

Carillon Tower Advisers first reported a position in TGTX in Q2 2020 and has held it in 3 quarters since. 247 funds tracked by Wall St. Rank hold TGTX as of Q4 2020.

  • Carillon Tower Advisers held 992,041 shares of TG Therapeutics worth $51.6M as of Q4 2020.
  • Carillon Tower Advisers sold 49,302 TG Therapeutics shares in Q4 2020, an estimated $1.67M.
  • TG Therapeutics made up 0.31% of Carillon Tower Advisers's portfolio in Q4 2020, its #106 holding.
  • Carillon Tower Advisers first reported a position in TG Therapeutics in Q2 2020 and has held it in 3 quarters since.
  • 247 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.